MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Quanterix Corp

Закрыт

СекторЗдравоохранение

6.23 -7.29

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

6.14

Макс.

6.7

Ключевые показатели

By Trading Economics

Доход

-4.3M

-12M

Продажи

-249K

35M

Прибыль на акцию

-0.3

Рентабельность продаж

-33.07

Сотрудники

471

EBITDA

-3.8M

-15M

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

+115.77% upside

Дивиденды

By Dow Jones

Следующий отчет о доходах

6 мая 2025 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

-107M

254M

Предыдущая цена открытия

13.52

Предыдущая цена закрытия

6.23

Техническая оценка

By Trading Central

Уверенность

Strong Bearish Evidence

Quanterix Corp График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

3 апр. 2025 г., 23:04 UTC

Главные новости

JPMorgan Raises Risk of U.S., Global Recession to 60%

3 апр. 2025 г., 22:40 UTC

Главные движущие силы рынка

Aldeyra Shares Fall on FDA Complete Response Letter for Dry Eye Disease Drug

3 апр. 2025 г., 22:18 UTC

Приобретения, слияния, поглощения

Quantum Corp. Gets Strategic Investment, Names New Financial Chief

3 апр. 2025 г., 18:51 UTC

Приобретения, слияния, поглощения

Capital One, Discover Merger Clears Regulatory Hurdle, Sources Tell The New York Times

3 апр. 2025 г., 23:43 UTC

Обсуждения рынка

Gold Steady, Supported by Potential Safe-Haven Demand -- Market Talk

3 апр. 2025 г., 23:41 UTC

Обсуждения рынка

Nikkei May Fall as U.S. Tariffs Raise Concerns About Global Growth -- Market Talk

3 апр. 2025 г., 22:22 UTC

Приобретения, слияния, поглощения

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

3 апр. 2025 г., 22:21 UTC

Приобретения, слияния, поглощения

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

3 апр. 2025 г., 21:43 UTC

Главные новости
Отчет

The Day Trump's Tariffs Shook Wall Street and Corporate America -- 5th Update

3 апр. 2025 г., 20:50 UTC

Обсуждения рынка

Financial Services Roundup: Market Talk

3 апр. 2025 г., 20:50 UTC

Обсуждения рынка

Tech, Media & Telecom Roundup: Market Talk

3 апр. 2025 г., 20:50 UTC

Обсуждения рынка

Basic Materials Roundup: Market Talk

3 апр. 2025 г., 20:43 UTC

Обсуждения рынка

Plummeting Toronto Home Sales Reflect Trade, Political Uncertainty -- Market Talk

3 апр. 2025 г., 20:34 UTC

Главные новости

Trump's Tariffs Were Supposed to Boost the Dollar, But Here's Why the Opposite Happened -- Heard on the Street -- 2nd Update

3 апр. 2025 г., 20:23 UTC

Главные новости

Trump Tariffs Send Dow Industrials to 1600-Point Decline; Dollar Slumps -- WSJ

3 апр. 2025 г., 20:15 UTC

Приобретения, слияния, поглощения

Blackstone Life Sciences And Anthos Therapeutics Announce Novartis Has Completed The Acquisition Of Anthos Therapeutics In A Deal Valued At Up To $3.1B, With $925M Paid Upfront >BX

3 апр. 2025 г., 19:55 UTC

Обсуждения рынка

Global Forex and Fixed Income Roundup: Market Talk

3 апр. 2025 г., 19:55 UTC

Обсуждения рынка

Dollar Weakens as Investors Seek Safety Elsewhere -- Market Talk

3 апр. 2025 г., 19:21 UTC

Обсуждения рынка

Oil Futures Slide on U.S. Tariffs, OPEC+ Output Plan -- Market Talk

3 апр. 2025 г., 19:15 UTC

Обсуждения рынка

U.S. Natural Gas Stays Focused on Weather, Storage -- Market Talk

3 апр. 2025 г., 18:45 UTC

Обсуждения рынка

Market Talk Roundup: Latest on U.S. Politics

3 апр. 2025 г., 18:45 UTC

Обсуждения рынка

Gold Drops In Tariff Fallout -- Market Talk

3 апр. 2025 г., 18:39 UTC

Обсуждения рынка

U.S. Tariffs Could Give Natural Gas Edge Over Solar -- Market Talk

3 апр. 2025 г., 18:38 UTC

Главные новости

Trump Tariffs Send Dow Industrials to 1400-Point Decline; Dollar Slumps -- WSJ

3 апр. 2025 г., 18:30 UTC

Главные новости

Auto Industry Braces for Major Pain From Trump's Tariffs -- Analysis

3 апр. 2025 г., 18:20 UTC

Обсуждения рынка

Uncertainty Still Roils Companies in Tariff Saga -- Market Talk

3 апр. 2025 г., 18:18 UTC

Обсуждения рынка

Market Talk Roundup: Latest on U.S. Politics

3 апр. 2025 г., 18:17 UTC

Обсуждения рынка

U.S. Workers Can't Match International Labor as Companies Consider Moving Supply Chains -- Market Talk

3 апр. 2025 г., 18:04 UTC

Обсуждения рынка

US Sees More Job Openings in Construction, Transportation -- Market Talk

3 апр. 2025 г., 17:55 UTC

Обсуждения рынка

Global Forex and Fixed Income Roundup: Market Talk

Сравнение c конкурентами

Изменение цены

Quanterix Corp Прогноз

Целевая цена

By TipRanks

115.77% рост

Прогноз на 12 месяцев

Средняя 14.5 USD  115.77%

Максимум 18 USD

Минимум 10 USD

Основано на мнении 4 аналитиков Wall Street, спрогнозировавших целевые цены для Quanterix Corp на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

4 ratings

3

Покупка

1

Удержание

0

Продажа

Техническая оценка

By Trading Central

6.16 / 6.91Поддержка и Сопротивление

Краткосрочная

Strong Bearish Evidence

Среднесрочная

Weak Bullish Evidence

Долгосрочная

No Evidence

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Quanterix Corp

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, it offers contract research services, including sample testing, homebrew assay development, custom assay development, lucent diagnostic, and LDT testing services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.